Abstract
A xenogeneic DNA vaccination has been licensed for use in dogs with locally controlled stage II and III oral malignant melanoma (OMM). At present, there are limited outcome data for dogs with OMM treated with surgery and immunotherapy. The aim of this study is to retrospectively review the outcome and survival of 32 dogs affected by OMM that were treated with a combination of surgery and the xenogeneic DNA vaccination (with the addition of radiotherapy in some cases) and to determine the influence of surgical margins and delay in receiving vaccination. The overall median survival time (MST) was 335 days (95% CI: 301-540 days), and the overall median progression-free survival (PFS) was 160 days (mean 182 days, 95% CI: 132-232 days). Stage, completeness of surgical margins and delay in administration of the vaccine did not appear to statistically influence survival or PFS, although these results may reflect the low statistical power of the study due to small numbers. Further studies are required to assess whether the addition of any adjuvant treatment to surgery, including immunotherapy, is able to significantly prolong survival in cases of canine oral melanoma.
References
Jan 1, 1979·Veterinary Pathology·D E Bostock
Nov 1, 1991·Veterinary Surgery : VS·J K KosovskyA K Patnaik
Sep 1, 1992·Veterinary Surgery : VS·J WallaceA K Patnaik
Jan 1, 1986·Cancer Investigation·E G MacEwenR Matus
Jan 1, 1985·The American Journal of Dermatopathology·M H Goldschmidt
Sep 1, 1980·Veterinary Pathology·D E Bostock, M T Dye
Jul 1, 1994·Journal of Veterinary Internal Medicine·K E BatemanS A Kruth
May 10, 2001·Journal of the American Veterinary Medical Association·K M RassnickA S Moore
Feb 5, 2003·Journal of Veterinary Internal Medicine·Kim P FreemanGlen K King
Jun 21, 2003·Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·David R ProulxDonald E Thrall
Feb 10, 2004·Journal of the American Veterinary Medical Association·Pedro A BoriaDeborah W Knapp
Sep 29, 2005·Vaccine·P J BergmanJ D Wolchok
Apr 9, 2008·Journal of Immunotherapy·Henrik von EulerThomas H Tötterman
Dec 1, 2005·Veterinary and Comparative Oncology·S MurphyA H Sparkes
Apr 13, 2011·The Veterinary Journal·Saray Lorda MayayoSelina Iussich
Dec 1, 2011·American Journal of Veterinary Research·Deborah A GrosenbaughJedd D Wolchok
Jun 29, 2012·Veterinary and Comparative Oncology·G DankG Segev
Aug 24, 2012·New Zealand Veterinary Journal·L K BrockleyP F Bennett
Jun 27, 2013·Journal of Immunotherapy·Sara WestbergHenrik von Euler
Aug 6, 2013·Veterinary and Comparative Oncology·J M OttnodJ E Obradovich
Jul 31, 2014·Journal of the American Veterinary Medical Association·Sarah E BostonPaolo Buracco
Citations
May 6, 2016·Veterinary and Comparative Oncology·L A PirasP Buracco
Jan 18, 2017·The Journal of Small Animal Practice·S VergantiS Murphy
Jun 8, 2017·World Journal of Experimental Medicine·Liliana M E Finocchiaro, Gerardo C Glikin
Jul 3, 2019·Genes·Anaïs Prouteau, Catherine André
Jun 22, 2019·Cancer Immunology, Immunotherapy : CII·Lidia TaroneFederica Riccardo
Apr 24, 2020·Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·Michelle TurekScott Hetzel
Aug 29, 2019·Veterinary and Comparative Oncology·Anais ProuteauBenoît Hédan
Apr 26, 2019·Scientific Reports·K L Bowlt BlacklockM Starkey
Jan 11, 2020·Frontiers in Oncology·Ginevra BroccaMassimo Castagnaro
Mar 15, 2018·International Journal of Molecular Sciences·Giuseppina BarutelloFederica Riccardo
Feb 15, 2019·Veterinary Sciences·Ramón M Almela, Agustina Ansón
Jan 15, 2021·Veterinary and Comparative Oncology·Mariateresa CamerinoPaolo Buracco
Mar 12, 2021·Advanced Drug Delivery Reviews·Lisa A Mestrinho, Ricardo R Santos
Mar 12, 2021·Gene·Yasunori HinoNaoki Miura
Mar 23, 2021·Veterinary and Comparative Oncology·Davide GiacobinoPaolo Buracco